NYSE · BMY
Bristol – Myers Squibb Co.
$62.56 +$0.47 (+0.76%) 1D After hours
Session Pulse
After hours
1
mentions on Fri
No new SEC filings since Tue close
its sector ranked
5/11
this week
Full pulse →
Key Metrics
$126.79B
Market cap
—
P/E · TTM
—
Revenue · TTM
—
Net income
EPS · TTM
—
Dividend yield
—
Free cash flow
—
Beta · 1Y
0.19
EBITDA · TTM
—
Gross margin
—
Snapshot
Market cap$126.79B
Enterprise value—
Shares outstanding2.0B
52-wk range$42.52 – $63.44
Avg volume · 20D12.3M
Net cash
—
Book value / share—
IndustryPharmaceutical Preparations
ExchangeNYSE
About Bristol – Myers Squibb Co.
IPO dateJun 23, 1952
Employees32500
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—
Profitability
Gross
—
Operating
—
Net
—
FCF
—
ROE / ROIC
— · —
Financial Health
Current ratio—
Quick ratio—
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital—
Cash Flow · TTM
Operating CF
—
Capex
—
Free cash flow
—
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
—
Needs two fiscal years of filings
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
—
Requires positive earnings and book value